Selected article for: "cell type and infected cell"

Author: Kumari G. Lokugamage; Adam Hage; Craig Schindewolf; Ricardo Rajsbaum; Vineet D. Menachery
Title: SARS-CoV-2 is sensitive to type I interferon pretreatment
  • Document date: 2020_3_9
  • ID: 2w0zr9c0_28
    Snippet: To further evaluate type I IFN induction, we examined both STAT1 phosphorylation and 135 ISG expression following infection of Calu3 2B4 cells at 48 hours. Examining Calu3 cell protein 136 lysates, we found cells infected with SARS-CoV-2 induced phosphorylated STAT-1 by 48 hours 137 post infection (Fig. 3B) . These results correspond to type I IFN treated Vero cell findings (Fig. 138 2) and suggest that the novel CoV is unable to completely inhi.....
    Document: To further evaluate type I IFN induction, we examined both STAT1 phosphorylation and 135 ISG expression following infection of Calu3 2B4 cells at 48 hours. Examining Calu3 cell protein 136 lysates, we found cells infected with SARS-CoV-2 induced phosphorylated STAT-1 by 48 hours 137 post infection (Fig. 3B) . These results correspond to type I IFN treated Vero cell findings (Fig. 138 2) and suggest that the novel CoV is unable to completely inhibit the IFN-I response. In contrast, 139 SARS-CoV had no evidence for STAT1 phosphorylation Calu3 cells, illustrating robust control 140 over IFN-I induction pathways. Similar to the Vero IFN pretreatment, augmented levels of total 141 STAT1 was observed in SARS-CoV-2 relative SARS-CoV, although with not as dramatic an 142 increase. Similarly, TRIM25 was found to be reduced in both SARS-CoV and SARS-CoV-2 143

    Search related documents:
    Co phrase search for related documents